{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T05:19:01Z","timestamp":1737091141288,"version":"3.33.0"},"reference-count":0,"publisher":"Care Comm","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ceska Gynekol"],"published-print":{"date-parts":[[2024,12,31]]},"abstract":"<jats:p>Objective: We aimed to compare highly purified human menopausal gonadotropin (hp-hMG) and recombinant follicle stimulating hormone (rFSH) in short antagonist in vitro fertilization (IVF) cycles of patients with poor ovarian reserve (POR). Limited research exists on this comparison in short antagonist cycles for this patient group. Materials and methods: This retrospective cohort study involved 165 POR patients aged 18\u201345 years who underwent IVF between 2018 and 2022. Patients were divided into two groups based on their GnRH antagonist protocol: hp-hMG (group 1 = 72) and rFSH (group 2 = 93). We compared pregnancy outcomes, number of oocytes collected, mature oocytes retrieved, mean fertilized oocytes, top quality embryos transferred, and serum estradiol (E2) and progesterone (P) levels on human chorionic gonadotropin (hCG) administration day. Results: No significant differences were found in E2 and P levels on hCG trigger day, endometrial thickness on transfer day, stimulation duration, total oocyte number, and mature oocyte number (P &gt; 0.05). The total gonadotropin dose was significantly higher in the rFSH group (P &lt; 0.001). The number of top-quality embryos transferred and clinical pregnancy and live birth rates did not diff er significantly between groups (P = 0.320; P = 0.310; P = 0.652; and P = 0.662, resp.). Conclusion: Neither hp-hMG nor rFSH showed superiority in patients with POR, indicating similar effectiveness in this population. \n\nKey words: highly purified human menopausal gonadotropin \u2013 in vitro fertilization \u2013 live birth \u2013 poor ovarian reserve \u2013 recombinant follicle stimulating hormone <\/jats:p>","DOI":"10.48095\/cccg2024469","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T14:02:29Z","timestamp":1737036149000},"page":"469-474","source":"Crossref","is-referenced-by-count":0,"title":["Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection"],"prefix":"10.48095","volume":"89","author":[{"name":"IVF unit, Department of Obstetrics and Gynecology, University of Health Sciences, Konya City Hospital, Turkey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilay Gok","family":"Korucu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Humeyra","family":"Akgun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmut Sami","family":"Tutar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukran","family":"Dogru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oguzhan","family":"Gunenc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"28151","published-online":{"date-parts":[[2024,12,31]]},"container-title":["\u010cesk\u00e1 gynekologie"],"original-title":["Srovn\u00e1n\u00ed vysoce purifikovan\u00e9ho lidsk\u00e9ho menopauz\u00e1ln\u00edho gonadotropinu a\u00a0rekombinantn\u00edho folikulostimula\u010dn\u00edho hormonu u\u00a0pacientek s\u00a0nedostate\u010dnou ovari\u00e1ln\u00ed rezervou podstupuj\u00edc\u00edch intracytoplazmatickou injekci spermie"],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T14:02:34Z","timestamp":1737036154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cs-gynekologie.cz\/en\/journals\/czech-gynaecology\/2024-6-8\/comparing-highly-purified-human-menopausal-gonadotropin-and-recombinant-follicle-stimulating-hormone-in-poor-ovarian-reserve-patients-undergoing-intracytoplasmic-sperm-injection-139548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,31]]},"published-print":{"date-parts":[[2024,12,31]]}},"URL":"https:\/\/doi.org\/10.48095\/cccg2024469","relation":{},"ISSN":["1210-7832","1805-4455"],"issn-type":[{"value":"1210-7832","type":"print"},{"value":"1805-4455","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}